Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, Pham K, Palmieri M, Tie J, Grogan T, Gibbs P, Sieber O, Waring P, Desai J. Day F, et al. Among authors: muranyi a. Target Oncol. 2015 Mar;10(1):99-109. doi: 10.1007/s11523-014-0319-8. Epub 2014 May 27. Target Oncol. 2015. PMID: 24859797 Free PMC article.
Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.
Ghosh P, Tie J, Muranyi A, Singh S, Brunhoeber P, Leith K, Bowermaster R, Liao Z, Zhu Y, LaFleur B, Tran B, Desai J, Jones I, Croxford M, Jover R, Goel A, Waring P, Hu S, Teichgraber V, Rohr UP, Ridder R, Shanmugam K, Gibbs P. Ghosh P, et al. Among authors: muranyi a. Clin Cancer Res. 2016 Jul 15;22(14):3488-98. doi: 10.1158/1078-0432.CCR-15-2290. Epub 2016 Mar 30. Clin Cancer Res. 2016. PMID: 27029492 Free PMC article.
Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.
Rohr UP, Herrmann P, Ilm K, Zhang H, Lohmann S, Reiser A, Muranyi A, Smith J, Burock S, Osterland M, Leith K, Singh S, Brunhoeber P, Bowermaster R, Tie J, Christie M, Wong HL, Waring P, Shanmugam K, Gibbs P, Stein U. Rohr UP, et al. Among authors: muranyi a. Ann Oncol. 2017 Aug 1;28(8):1869-1875. doi: 10.1093/annonc/mdx207. Ann Oncol. 2017. PMID: 28460000 Free article.
Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis.
Yoon HH, Shi Q, Heying EN, Muranyi A, Bredno J, Ough F, Djalilvand A, Clements J, Bowermaster R, Liu WW, Barnes M, Alberts SR, Shanmugam K, Sinicrope FA. Yoon HH, et al. Among authors: muranyi a. Clin Cancer Res. 2019 Jan 1;25(1):125-133. doi: 10.1158/1078-0432.CCR-18-1984. Epub 2018 Oct 9. Clin Cancer Res. 2019. PMID: 30301825 Free PMC article.
Artificial Intelligence-Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in RAS Wild-Type Metastatic Colorectal Cancer.
Williams CJM, Seligmann JF, Elliott F, Shires M, Richman SD, Brown S, Zhang L, Singh S, Pugh J, Xu XM, Muranyi A, Guetter C, Lorsakul A, Kurkure U, Zhao Z, Martin J, Wang X, Nguyen K, Liu WW, Yan D, West NP, Barrett JH, Barnes M, Bai I, Seymour MT, Quirke P, Shanmugam K. Williams CJM, et al. Among authors: muranyi a. Clin Cancer Res. 2021 Jun 15;27(12):3422-3431. doi: 10.1158/1078-0432.CCR-21-0120. Epub 2021 Apr 22. Clin Cancer Res. 2021. PMID: 33888518
Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.
Jary M, Liu WW, Yan D, Bai I, Muranyi A, Colle E, Brocheriou I, Turpin A, Radosevic-Robin N, Bourgoin P, Penault-Llorca F, Cohen R, Vernerey D, André T, Borg C, Shanmugam K, Svrcek M. Jary M, et al. Among authors: muranyi a. Mol Oncol. 2022 Jun;16(11):2260-2273. doi: 10.1002/1878-0261.13173. Epub 2022 Feb 9. Mol Oncol. 2022. PMID: 34954864 Free PMC article. Clinical Trial.
Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer.
Raghav K, Loree JM, Morris JS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Korphaisarn K, Kee B, Muranyi A, Singh S, Routbort M, Chen K, Shaw KRM, Katkhuda R, Shanmugam K, Maru D, Fakih M, Kopetz S. Raghav K, et al. Among authors: muranyi a. JCO Precis Oncol. 2019 Dec;3:1-13. doi: 10.1200/PO.18.00226. JCO Precis Oncol. 2019. PMID: 35100667
65 results